

FOR IMMEDIATE RELEASE

Sun Pharma acquires Disperzyme® and Phlogam® brands to strengthen its anti-inflammatory portfolio

- *Disperzyme and Phlogam are fixed dose combination of proteolytic enzymes and bioflavonoid viz., Trypsin, Bromelain and Rutoside ("TBR").*
- *1st brands in Trypsin, Bromelain and Rutoside (TBR) category to complete clinical study in India and get approval of Drugs Controller General of India.*

Mumbai, India, January 30, 2023 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that it has acquired three brands viz. Disperzyme® (Trypsin BP 96 mg, Bromelain 180 mg & Rutoside Trihydrate 200 mg), Disperzyme-CD® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) and Phlogam® (Trypsin BP 48 mg, Bromelain 90 mg & Rutoside Trihydrate 100 mg) from Aksigen Hospital Care ("Aksigen"), a Mumbai based research driven healthcare entity with more than two decades of experience in the healthcare field. All the brands are approved by the Drugs Controller General of India ("DCGI") for post-operative inflammation in patients undergoing minor surgery and dental procedures.

Disperzyme® and Phlogam® are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside ("TBR") to complete a clinical study in India and get DCGI approval. The brands were registered and launched in India by Aksigen in 2013.

Kirti Ganorkar, CEO-India business, Sun Pharma, said, "The addition of Disperzyme® and Phlogam® further strengthens our anti-inflammatory portfolio. This systemic enzyme therapy combination is being used to control edema and it speeds-up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation."

The overall market of proteolytic enzyme for healing, pain and edema in India is around Rs.500 crores (as per IQVIA data MAT Nov 2022).

About Disperzyme® and Phlogam®:

Actions of Trypsin, a proteolytic enzyme is primarily related to enhancing fibrinolysis by making more plasmin available for action. The addition of Bromelain, a proteolytic enzyme not only complements the fibrinolytic action of Trypsin, but also has broad ranging effects of limiting vascular permeability (which can help counter edema), inhibiting platelet aggregation (which can help counter dysregulated coagulation and thrombosis) and limiting inflammatory cell infiltration. Rutoside a bioflavonoid, on the other hand, has far-reaching effects in controlling the oxidative stress, vascular permeability and countering the activation of and further release of inflammatory cytokines and chemokines. When combined, these ingredients not only cover

Registered Office : SPARC, Tandajja, Vadodara – 390 012 India.

Reaching People. Touching Lives

Sun Pharmaceutical Industries Ltd.
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



a wider range of processes involved in inflammation, but they also complement each other's actions and provide a more well-rounded control of the inflammatory process¹. Overall, TBR, the systemic enzyme therapy, intervenes in different processes: the release of inflammatory mediators, the modulation of adhesion molecules, and the activation of fibrinolysis with consequent improved healing^{2,3}.

Disperzyme[®] and Phlogam[®], administered orally, offers systemic enzyme-flavonoid therapy. The safety and efficacy of fixed dose combination of trypsin, bromelain and rutoside viz, Disperzyme[®] and Phlogam[®] was assessed versus serratiopeptidase in 303 subjects with post-operative inflammation undergoing minor surgery and dental procedures. The study demonstrated systemic enzyme therapy with trypsin-bromelain-rutoside combination provided significantly better control and resolution of post-operative pain and inflammation, compared to serratiopeptidase. Disperzyme[®] and Phlogam[®] provides the clinicians an evidence-based management solution for inflammation and pain management after minor surgery and dental procedures.

References:

1. International Journal of Basic & Clinical Pharmacology John J et al. Int J Basic Clin Pharmacol. 2022 Nov;11(6)
2. Walad M, Honzikova M, Lysikova M. Systemic enzyme support: an overview. Nutrition News. 2008;4:2-5.
3. Shahid SK, Turakhia NH, Kundra M, Shanbag P, Daftary GV, Schiess W. Efficacy and safety of Phlogenzym-A protease formulation, in sepsis in children. JAPI. 2002;50:527-31.

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live

Contacts:

Investors:

Dr. Abhishek Sharma
Tel +91 22 4324 4324, Xtn 2929
Tel (D) +91 22 4324 2929
Mobile +91 98196 86016
E mail abhi.sharma@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel (D) +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com

Registered Office : SPARC, Tandalja, Vadodara – 390 012 India.

Reaching People. Touching Lives